about
Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models.(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directionsPharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancerAcinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy.A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.Hepatocellular carcinoma following renal transplantation.A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.A case of advanced gastric cancer.Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency.FOLFIRINOX Induction Therapy for Stage 3 Pancreatic AdenocarcinomaTreatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma.Young patients with synchronous colorectal liver metastases.Identification of germline genetic mutations in patients with pancreatic cancer.Targeted therapies for pancreatic adenocarcinoma.Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers.Novel Therapeutics for Pancreatic Adenocarcinoma.Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.Systemic therapy for biliary cancers.Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Current management and future directions in metastatic pancreatic adenocarcinoma.The role of novel biologics in biliary cancers.Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes.A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model.Re: Lymphopenia associated with adjuvant anthracycline/taxane regimens.A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients.Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy.In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review.Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
P50
Q27310815-4FB0534D-BB59-453E-938C-976DA7832AF3Q33424573-9EC81F7C-3402-4F0C-9118-EDB10E044B40Q34632472-02A56A85-CF07-45D7-8BD2-4F23C34C13DBQ35137142-4F585506-DD29-4DDA-BFEF-49791F49E317Q35642368-564F4403-B3DF-497A-8C0A-5F5DB9C29D1AQ35703105-3BF26B08-1CBC-4DBC-880D-238722FA97D5Q35715435-C243FBE4-5084-4246-B25C-C7401624FE93Q35903399-C420BCB4-BE99-411C-88E9-437774637254Q36014962-A9145875-3889-4BCD-9F30-2444E2245E2AQ36187672-A687EC8C-903D-4868-A115-B048F723B712Q36848552-E4D928E2-373B-46C0-A561-0C830958647DQ37168250-FDFFB1E8-E198-4FE8-90DD-1479776F358BQ37445913-9BC2A253-7DE8-45EC-B11D-2D707054AEF5Q37540235-7E32DFEC-2BF8-40DB-8EFC-0831791FCBEAQ37622020-D2193008-CE23-430D-A528-A8B30319A466Q38063110-D23CB5FA-9F92-44EE-B7EF-C40570B62A8EQ38557730-C7586591-C0F1-4A2D-913C-E96D6DD353D4Q38735426-CB3F7D88-8C0B-4EAD-AE58-298752E09764Q38797017-B1E34D1D-C60C-45EA-922F-66B77324E8D7Q38798543-22A21390-8C2E-46A6-B773-0AE2014E6841Q38819470-7F8F700F-DB43-40F0-80EB-26266E779291Q38941427-D93C0623-AF1A-4755-A745-3A9D1D7D4327Q39171689-C4562AA7-0E96-4F3C-A8BD-A4B6D0F7A331Q39673531-0E9C1959-0698-4195-82C0-BA280CBC47F0Q40141235-B5D4374D-9BB9-4416-B846-EFF1A30A2797Q40327923-9FEFAF88-B24D-452C-A57F-197EE915A650Q41202462-36310C78-29A2-462F-9BC4-B2F8F802B801Q43236869-2445A284-75C1-4C41-A2B2-C2F23D9BF93AQ43601788-E009CD77-E77C-4445-9EC2-45FDF7E8D3C0Q47101670-BD8AD0D5-6C5F-4FA9-88AC-7904DB4BB634Q47107059-2038B751-9CC2-40B1-A5C3-196DEC316C0FQ47109380-077F1FC3-6113-4332-A25F-E012A29A6FCCQ47202217-7017776F-3B67-48AC-9258-03E8914C9117Q47403256-374ED477-8EA2-4E08-AE78-479907DB8134Q47558771-03C83C2F-6191-4E67-B323-F83E669ADFBFQ47713578-DCFD1109-3C4B-4068-8466-E5C32E60994CQ48013101-C5736B50-A462-43E0-BF9F-CD08878B2B5CQ48234878-18FDD0F2-8B24-4075-A335-AF2514D4568AQ48575438-967C398B-7EB8-47DB-B415-F60E9D6787A2Q50222046-BBCC96AD-F074-4541-9F67-DA6D3A47A872
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maeve Lowery
@ast
Maeve Lowery
@en
Maeve Lowery
@es
Maeve Lowery
@nl
Maeve Lowery
@sl
type
label
Maeve Lowery
@ast
Maeve Lowery
@en
Maeve Lowery
@es
Maeve Lowery
@nl
Maeve Lowery
@sl
altLabel
Lowery M
@en
Lowery M.A.
@en
Lowery MA
@en
prefLabel
Maeve Lowery
@ast
Maeve Lowery
@en
Maeve Lowery
@es
Maeve Lowery
@nl
Maeve Lowery
@sl
P106
P1153
36102517900
P21
P31
P496
0000-0003-1354-7606